Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium channel subfamily K member 9 (KCNK9), also known as TASK-3, is a two-pore domain potassium channel (K2P) that contributes to background or "leak" potassium currents. It stabilizes resting membrane potential and regulates cellular excitability, particularly in neurons. KCNK9 is widely expressed, especially in the brain (cerebellum), pancreas, and placenta. Mutations in KCNK9, particularly when maternally inherited due to genomic imprinting, cause KCNK9 imprinting syndrome, characterized by congenital hypotonia, feeding difficulties, intellectual disability, and delayed development. Its activity is modulated by extracellular pH, arachidonic acid, and phorbol esters.
Not applicable; the description provided does not include any drugs that target this molecule. However, it does mention inhibition by arachidonic acid and phorbol esters, which can be explored further.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium Channel Subfamily K Member 9 (KCNK9).